Context Therapeutics, Inc. (CNTX)
0.16
-0.01
(-5.10%)
USD |
NASDAQ |
Nov 20, 16:00
0.1597
0.00 (0.00%)
After-Hours: 20:00
Context Therapeutics Research and Development Expense (TTM) : 37.10M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 37.10M |
| June 30, 2026 | 40.11M |
| March 31, 2026 | 35.41M |
| December 31, 2025 | 31.86M |
| September 30, 2025 | 22.53M |
| June 30, 2025 | 30.64M |
| March 31, 2025 | 24.19M |
| December 31, 2024 | 22.70M |
| September 30, 2024 | 25.48M |
| June 30, 2024 | 13.14M |
| March 31, 2024 | 15.22M |
| December 31, 2023 | 17.78M |
| Date | Value |
|---|---|
| September 30, 2023 | 14.63M |
| June 30, 2023 | 12.22M |
| March 31, 2023 | 10.77M |
| December 31, 2022 | 7.591M |
| September 30, 2022 | 6.740M |
| June 30, 2022 | 5.402M |
| March 31, 2022 | 4.718M |
| December 31, 2021 | 3.805M |
| September 30, 2021 | 2.980M |
| June 30, 2021 | 2.607M |
| March 31, 2021 | 1.485M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| EyePoint, Inc. | 296.65M |
| Neumora Therapeutics, Inc. | 135.16M |
| LENZ Therapeutics, Inc. | 0.00 |
| ANI Pharmaceuticals, Inc. | 50.60M |
| Corcept Therapeutics, Inc. | 241.72M |